Physician profile
James G Nee
NPI 1932159282
$493.87
in general payments reported to CMS, 2019-2025
14 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $17.19 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $77.39 | 2025 | Apretude |
| Exact Sciences Corporation | $60.64 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Gilead Sciences, INC. | $48.06 | 2025 | |
| Pfizer INC. | $45.11 | 2025 | |
| Abbvie INC. | $40.97 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $34.82 | 2025 | Zoryve |
| Corium, LLC | $29.53 | 2025 | Azstarys |
| Lilly USA, LLC | $29.28 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $23.48 | 2025 | Ozempic |
| Amgen INC. | $23.33 | 2025 | Repatha |
| Biotronik Nro, INC. | $21.54 | 2025 | Prospera |
| Tris Pharma INC | $20.80 | 2025 | Dyanavel Xr |
| Braeburn INC. | $19.66 | 2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $19.26 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Nee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.